Donate to Malaria Consortium
100% of your donation (minus credit card fees, if applicable) goes to the cause of your choice. Rethink Charity Forward will strive to extend its “zero fees” initiative indefinitely.
If you are making a donation of $1000 or more, or a monthly donation of $200 or more, please send an email to firstname.lastname@example.org so we can provide you with alternative donation options that could cut back significantly on third-party fees.
Malaria Consortium is one of the world’s leading non-profit organisations specializing in the prevention, control and treatment of malaria and other communicable diseases among vulnerable populations.
All dollar and gift amounts on this donation page are in Canadian Dollars (CAD).
Seasonal malaria chemoprevention
Malaria is preventable and treatable, but many children living in Africa die from malaria before their fifth birthday. Malaria Consortium has proven the feasibility and impact of seasonal malaria chemoprevention (SMC) at scale. SMC, which consists four monthly doses of sulfadoxine-pyrimethamine plus amodiaquine (SP + AQ), is recommended by the World Health Organization (WHO) as one of the most effective interventions for the prevention of malaria in areas where malaria transmission is highly seasonal and resistance to SP + AQ is low, such as the Sahel region of sub-Saharan Africa. With areas in the Sahel having the highest incidence of malaria in the world, it is now an urgent priority to close the gap and reach all eligible children.
SMC has been shown to be highly effective and feasible for the prevention of malaria among children in areas where the malaria transmission season is no longer than four months. It involves administering up to four monthly doses of antimalarial drugs to children aged 3-59 months during peak malaria transmission season. Since it was approved by the WHO, SMC has been found to prevent up to 89 percent of malaria cases.
SMC is also highly cost-effective in preventing malaria. Malaria Consortium led costing studies in seven countries to estimate the provider cost of SMC in 2015 (US $1 per child per month) and in 2016 (US $0.85 per child per month), giving estimates of the average cost per child for one year of US $3.40 to protect a child during the rainy season from malaria with SMC.
What Malaria Consortium Is Doing
Malaria Consortium has been leading the way on SMC globally, initially through our pilot project in northern Nigeria in 2012-2014. From 2015 through 2017 MC led the Unitaid funded ACCESS-SMC project to scale up SMC coverage in seven Sahelian countries (Burkina Faso, Chad, Guinea Conakry, Mali, Niger, Nigeria, The Gambia). As a result, SMC was shown to be safe, inexpensive and effective. A total of 60,000 deaths and 10 million cases of malaria were estimated to have been averted.
After the end of the ACCESS SMC project Malaria Consortium has continued to deliver SMC to four million children in Nigeria, Burkina Faso and Chad though GiveWell-directed funding. In 2019 and 2020 we plan to reach over five million children.
Malaria Consortium works with every level of a country’s health system to deliver SMC. The organization supports each national government to develop high-level plans and policies, sharing its expertise in supply chain management, health worker training, community mobilization, safety monitoring and impact evaluation. Malaria Consortium ensures that all stakeholders are involved in the SMC delivery and evaluation process, from the National Malaria Control Program managers and health officials who set and execute the policies and plans, to the drivers who deliver the commodities, the community health workers who administer the treatments to children, and the supervisors who ensure quality of service delivery and data capture.
As well as training and mobilizing community health workers to deliver SMC, Malaria Consortium also arranges the dissemination of public health and behavior change communications materials to inform local people of the importance of the treatment and how they can access it. Malaria Consortium works with supply chain agencies to ensure a steady, reliable flow of the SMC drugs, from their arrival in country to the point of distribution, and that they are monitored and kept secure.
An estimated 28-34 million children are eligible for SMC, with an estimated gap of 12 to 18 million eligible who are not yet receiving SMC. The potential for SMC is enormous – from saving lives and reducing illness to preventing school absenteeism and boosting economic growth. If all children eligible for SMC had access to it, some 175,000 lives could be saved each year, and 18 million malaria cases could be prevented. It is urgent to close this gap and maximize the impact of this intervention. Malaria can be prevented, and in the Sahel and sub-Sahel regions of Africa SMC can make an important contribution.